Frovatriptan Succinate Hydrate

琥珀酸夫罗曲坦

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameFrovatriptan Succinate Hydrate
Drug Alias Name氟伐曲坦IsimigPitunal琥珀酸福伐曲坦琥珀酸夫罗曲坦水合物 +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsHeadache Disorders, SecondaryMigraine without AuraMigraine with Aura +[4] 
Global Approved IndicationsMigraine without AuraMigraine with AuraMigraine Disorders
Approved Indications in ChinaMigraine without AuraMigraine with Aura
Original Approved Country/TerritoryUnited States
Original Approved Date2001/11/08
Country/TerritoryCanadaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEndo Operations LtdUniversity Of CalgaryEndo Pharmaceuticals Inc +[5] 
Active IndicationsMigraine without AuraMigraine with Aura
Inactive IndicationsHeadache Disorders, SecondaryMigraine Disorders

Other Information

ATC CodeN02CC07
Related LinksDrugBank